Comprehensive splicing analysis of the alternatively spliced CHEK2 exons 8 and 10 reveals three enhancer/silencer‐rich regions and 38 spliceogenic variants
Open Access
- 9 February 2024
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 262 (4) , 395-409
Abstract
Splicing is controlled by a large set of regulatory elements (SREs) including splicing enhancers and silencers, which are involved in exon recognition. Variants at these motifs may dysregulate splicing and trigger loss‐of‐function transcripts associated with disease. Our goal here was to study the alternatively spliced exons 8 and 10 of the breast cancer susceptibility gene CHEK2 . For this purpose, we used a previously published minigene with exons 6–10 that produced the expected minigene full‐length transcript and replicated the naturally occurring events of exon 8 [Δ(E8)] and exon 10 [Δ(E10)] skipping. We then introduced 12 internal microdeletions of exons 8 and 10 by mutagenesis in order to map SRE‐rich intervals by splicing assays in MCF‐7 cells. We identified three minimal (10‐, 11‐, 15‐nt) regions essential for exon recognition: c.863_877del [ex8, Δ(E8): 75%] and c.1073_1083del and c.1083_1092del [ex10, Δ(E10): 97% and 62%, respectively]. Then 87 variants found within these intervals were introduced into the wild‐type minigene and tested functionally. Thirty‐eight of them (44%) impaired splicing, four of which (c.883G>A, c.883G>T, c.884A>T, and c.1080G>T) induced negligible amounts (A, c.886G>T, c.1075G>A, c.1075G>T, c.1076A>T, and c.1078G>T) showed significantly strong impacts (20–50% of the minigene full‐length transcript). Thirty‐three of the 38 spliceogenic variants were annotated as missense, three as nonsense, and two as synonymous, underlying the fact that any exonic change is capable of disrupting splicing. Moreover, c.883G>A, c.883G>T, and c.884A>T were classified as pathogenic/likely pathogenic variants according to ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology)‐based criteria. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.Keywords
Funding Information
- Ministerio de Ciencia e Innovación (PI20/00110, PI20/00225)
- Fundación Científica Asociación Española Contra el Cáncer
This publication has 66 references indexed in Scilit:
- Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenesBreast Cancer Research, 2012
- Functional roles of protein splicing factorsBioscience Reports, 2012
- Identification of Evolutionarily Conserved Exons as Regulated Targets for the Splicing Activator Tra2β in DevelopmentPLOS Genetics, 2011
- Compensatory signals associated with the activation of human GC 5′ splice sitesNucleic Acids Research, 2011
- A High Proportion of DNA Variants ofBRCA1andBRCA2Is Associated with Aberrant Splicing in Breast/Ovarian Cancer PatientsClinical Cancer Research, 2010
- Splicing in disease: disruption of the splicing code and the decoding machineryNature Reviews Genetics, 2007
- Building specificity with nonspecific RNA-binding proteinsNature Structural & Molecular Biology, 2005
- Missense, Nonsense, and Neutral Mutations Define Juxtaposed Regulatory Elements of Splicing in Cystic Fibrosis Transmembrane Regulator Exon 9Journal of Biological Chemistry, 2003
- Listening to silence and understanding nonsense: exonic mutations that affect splicingNature Reviews Genetics, 2002
- Chk2 kinase — a busy messengerNature Reviews Molecular Cell Biology, 2001